Indeed, in CTCL patients, a single dose of mogamulizumab decreased the fraction of CCR4-positive malignant T-cells, with a concomitant reduction of CCR4+ Tregs (223). The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.